Macroscopic Hematuria Segment has the Largest Share of Type in the North America Hematuria Treatment Market during 2021–2028

According to our latest study on “North America Hematuria Treatment Market Forecast to 2028 – COVID-19 Impact and Analysis – by Type, Treatment, Indication, and End User,” the market is projected to reach US$ 419.7 million by 2028 from US$ 351.6 million in 2021; it is expected to grow at a CAGR of 2.6% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the high prevalence of hematuria- associated indications, increasing awareness about treatment options and improving healthcare expenditure are factors propelling the hematuria treatment market. However, the undiagnosed cases of associated indications may hamper the growth of the North America hematuria treatment market in the forecast period.

The pandemic has offered vital growth opportunities for the players operating in the kidney disease market. The possibilities were due to the rising numbers of patients affected by the coronavirus. For instance, according to the American Society of Nephrology report, in response to COVID-19, half coronavirus positive patients admitted to intensive care unit (ICU) experience kidney failure that requires some form of dialysis. The report stated that ~ 10% to 50% of patients in ICU showed kidney failure, nearly 17% of patients needed urgent dialysis, and 46% had shown some forms of acute kidney injury (AKI). Across the North American region, the US has registered the highest numbers of patients affected by the coronavirus. Thus, the rising numbers of patients are at higher risk of getting affected for acute kidney injury (AKI), including tubular injury with septic shock, micro-inflammation, increased blood clotting, and probable direct infection of the kidney. Therefore, it is expected to raise the demand for kidney disease management products leading to market growth in the coming future.

Based on type, the North America hematuria treatment market is bifurcated into macroscopic hematuria, microscopic hematuria, idiopathic hematuria, and jogger’s hematuria. In 2021, the macroscopic hematuria segment is estimated to account for the largest market share. However, microscopic hematuria segment is estimated to register the highest CAGR during forecast period. Macroscopic hematuria is also known as gross hematuria. It is diagnosed by various methods such as blood tests, kidney biopsy, and others diagnosis techniques.

AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc.,Sun Pharmaceutical Industries Ltd, and Boehringer Ingelheim International GmbH are among the leading companies in the North America hematuria treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, AstraZeneca, in September 2021, the new plant will allow for late-stage development and early commercial supply, adopting state of the art process technology and digital innovation that is designed to meet the needs of the Company’s new medicines pipeline with speed and agility.

The market for hematuria treatment market is segmented into type, treatment, Indication, and end user. Based on type, the North America hematuria treatment market is segmented into macroscopic hematuria, microscopic hematuria, idiopathic hematuria, and jogger’s hematuria. Based on treatment, the hematuria treatment market is segmented drugs, therapies, and others. Based on indication, the hematuria treatment market is segmented into urinary tract infections, kidney stones, urethritis, blood cancer, bladder stones, prostate cancer, cystitis, trauma, vigorous exercise, polycystic kidney disease, endometriosis, and menstruation. Based on end user, the hematuria treatment market is segmented into hospitals, clinics, and Ambulatory Surgical Centers, and others. Geographically, the hematuria treatment market is segmented into North America (US, Canada, Mexico).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com